药品注册申请号:075091
申请类型:ANDA (仿制药申请)
申请人:MYLAN
申请人全名:MYLAN PHARMACEUTICALS INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG No No AB 1999/09/30 1999/09/30 Prescription
002 CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG No No AB 2000/04/21 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2015/05/27 SUPPL-26(补充) Approval Labeling STANDARD
2012/05/14 SUPPL-24(补充) Approval Labeling
2002/10/01 SUPPL-8(补充) Approval Manufacturing (CMC)
2002/06/12 SUPPL-7(补充) Approval Manufacturing (CMC)
2001/11/07 SUPPL-6(补充) Approval Labeling
2000/08/11 SUPPL-5(补充) Approval Manufacturing (CMC)
2000/08/11 SUPPL-4(补充) Approval Manufacturing (CMC)
2000/04/21 SUPPL-2(补充) Approval Labeling
2000/04/21 SUPPL-1(补充) Approval Manufacturing (CMC)
2000/02/04 SUPPL-3(补充) Approval Labeling
1999/09/30 ORIG-1(原始申请) Approval
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:CARBIDOPA; LEVODOPA 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:50MG;200MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
075091 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 1999/09/30 MYLAN
076521 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 2004/05/14 IMPAX LABS
076212 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 2004/06/16 APOTEX
077828 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 2007/08/23 SUN PHARM INDS
202323 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 2013/02/08 ACCORD HLTHCARE
210341 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No No AB 2019/06/05 ALEMBIC
214091 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 50MG;200MG Prescription No Yes AB 2021/10/05 SCIEGEN PHARMS INC
活性成分:CARBIDOPA; LEVODOPA 剂型/给药途径:TABLET, EXTENDED RELEASE;ORAL 规格:25MG;100MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
075091 002 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2000/04/21 MYLAN
076521 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2004/05/14 IMPAX LABS
076212 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2004/06/16 APOTEX
077828 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2007/08/23 SUN PHARM INDS
202323 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2013/02/08 ACCORD HLTHCARE
210341 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2019/06/05 ALEMBIC
214091 001 ANDA CARBIDOPA AND LEVODOPA CARBIDOPA; LEVODOPA TABLET, EXTENDED RELEASE;ORAL 25MG;100MG Prescription No No AB 2021/10/05 SCIEGEN PHARMS INC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database